Arcutis CFO sells 1,341 shares for tax withholding

Arcutis Biotherapeutics SVP and CFO Latha Vairavan disposed of 1,341 shares of Common Stock in a tax-related sale.

Rhea-AI Filing Summary

Arcutis Biotherapeutics SVP and CFO Latha Vairavan disposed of 1,341 shares of Common Stock in a tax-related sale. The shares were sold on May 4, 2026 at a weighted average price of $23.6106 per share.

According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units, rather than as a discretionary portfolio trade. After this transaction, Vairavan directly holds 86,413 shares of Arcutis Biotherapeutics common stock.

The sale price reflects multiple trades executed in a range from $23.16 to $23.93 per share, with the weighted average reported in the filing.

Insider Trade Summary 10b5-1

Net Seller: 1,341 shares

Net Sell 1 txn

Insider Vairavan Latha

Role SVP Chief Financial Officer

Sold 1,341 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,341	$23.6106	$32K

Holdings After Transaction: Common Stock — 86,413 shares (Direct)

Footnotes (2)

1. F1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 1,341 shares Weighted average sale price: $23.6106 per share Post-transaction holdings: 86,413 shares +1 more

4 metrics

Shares sold 1,341 shares Common Stock sold on May 4, 2026

Weighted average sale price $23.6106 per share Average price for 1,341 shares sold

Post-transaction holdings 86,413 shares Common Stock directly held by CFO after sale

Sale price range $23.16–$23.93 per share Range of individual trade prices within the sale

Key Terms

Restricted Stock Units, tax withholding obligations, weighted average sale price

3 terms

Restricted Stock Units financial

"vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the Reporting Person to cover tax withholding obligations"

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcutis Biotherapeutics (ARQT) report for CFO Latha Vairavan?

Arcutis Biotherapeutics reported that SVP and Chief Financial Officer Latha Vairavan sold 1,341 shares of common stock. The sale was executed to satisfy tax withholding obligations tied to vesting Restricted Stock Units, rather than as a discretionary open-market trade.

How many Arcutis (ARQT) shares does CFO Latha Vairavan hold after this Form 4 transaction?

After the reported transaction, CFO Latha Vairavan directly holds 86,413 shares of Arcutis Biotherapeutics common stock. This indicates the 1,341 shares sold for tax withholding represent a small portion of her overall equity position in the company.

At what price did the Arcutis (ARQT) CFO’s 1,341 shares sell in the Form 4 filing?

The 1,341 shares sold by Arcutis CFO Latha Vairavan carried a weighted average sale price of $23.6106 per share. The filing notes individual trades occurred within a price range from $23.16 to $23.93 per share.

Why did the Arcutis (ARQT) CFO sell 1,341 shares according to the Form 4 footnotes?

The footnotes state the 1,341 shares were sold solely to cover tax withholding obligations triggered by the vesting of Restricted Stock Units. This characterizes the transaction as tax-related rather than a discretionary decision to reduce equity exposure.

Does the Arcutis (ARQT) Form 4 indicate multiple trade prices for the CFO’s share sale?

Yes. While the filing reports a weighted average sale price of $23.6106, it explains that the 1,341 shares were sold in multiple transactions, with individual prices ranging from $23.16 to $23.93 per share, inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 06:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vairavan Latha

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		S(1)		1,341	D	$23.6106(2)	86,413	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

	/s/ Masaru Matsuda, as Attorney-in-Fact for Latha Vairavan	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)